Compare MRAM & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | ARVN |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.1M | 516.2M |
| IPO Year | 2016 | 2018 |
| Metric | MRAM | ARVN |
|---|---|---|
| Price | $19.14 | $8.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 19 |
| Target Price | ★ $18.50 | $15.05 |
| AVG Volume (30 Days) | ★ 2.0M | 771.2K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | $49,417,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $5.76 | $6.06 |
| 52 Week High | $51.50 | $14.22 |
| Indicator | MRAM | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 53.91 |
| Support Level | $8.77 | N/A |
| Resistance Level | $28.94 | $10.18 |
| Average True Range (ATR) | 2.48 | 0.44 |
| MACD | -0.52 | 0.17 |
| Stochastic Oscillator | 3.08 | 81.76 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.